Kornimate/medical-research-clean huggingface dataset:
enhanced respiratory polygraphy in suspected osa

Conditions: Sleep Apnea, Obstructive

Summary: obstructive sleep apnea (osa) remains underdiagnosed in 2022, as a result of the unawareness of its serious health-related consequences and the lack of diagnosis accessibility. respiratory polygraphy (pv) is widely used as a screening tool and sometimes a diagnosis test, although polysomnography (psg) remains the gold standard investigation as it provides complete information about sleep architecture and arousals. thus, it has been shown that the apnea hypopnea index (ahi) and respiratory disorder index (rdi) are underestimated by pv vs psg. approaches to substitute psg by simpler but equally efficient diagnosis tests have included devices aiming to record complementary signals and to analyze them with artificial intelligence. in this context, aseega algorithm has demonstrated its performance for automatic sleep scoring in healthy individuals and patients with various sleep disorders, based on a single channel eeg analysis. this study aims at comparing the real-life performance and feasibility of added single channel eeg automatic sleep scoring using aseega to pv versus standard pv and psg in adults referred to a regional sleep reference center for suspected osa. we hypothesize that this approach (1) is as accurate as psg and more accurate that pv for ahi analysis, and (2) is less time-consuming than psg.


Eligibility criteria:
inclusion criteria: - hospitalized at the center for sleep medicine and respiratory diseases, hôpital de la croix-rousse, lyon academic hospital, lyon between 09/2022 and 11/2022 for psg following suspected osa . exclusion criteria: * unreliable sleep scoring due to artefacts (\> 10% of the recording) or to epileptic abnormalities on the electroencephalography recordings * presence of other suspected sleep disorder: central hypersomnia, rapid-eye-movement (rem) or non-rem sleep parasomnia, sleep-related motor disorders... * ongoing psychotropic medication * opposition of the patient to the use of their data.

Keywords: polysomnography polygraphy single channel eeg automated sleep scoring
algometer and category ii pelvic blocking and cranial protocol

Conditions: Pain; Sacroiliac Joint Dysfunction

Summary: the purpose of this study is to evaluate the relationship of pelvic blocking and protocol for cranial adjusting with specific pain areas as outlined by dr. bertrand dejarnette in the category ii/sacroiliac protocol. an algometer will be used to determine the level of pain at specific points before and after each treatment of pelvic blocking with or without cranial adjusting.


Eligibility criteria:
inclusion criteria: * logan student, staff or faculty * age 18 - 60 * no chiropractic adjustment 2 weeks prior to beginning the study * show the dejarnette category ii indicators exclusion criteria: * previous lower extremity, first rib and spine injury, surgery * local infection, injury or other malignancy affecting the lower extremity and the nervous system * unstable joints of the lower extremity and/or first rib and/or spine * prescription or herbal muscle stimulants, relaxants, etc. that could affect the nervous system * contraindication to dejarnette category ii pelvis blocking * pregnancy * significant lower lumbar involvement * diabetes, shortness of breath on light physical activity, cardiovascular disease * numbness and/or tingling in the lower extremities

Keywords: sacroiliac joint dysfunction algometer chiropractic manual therapy indicator points associated with sacroiliac joint dysfunction
follow-up study of autologous adipose-derived stem cells (antg-asc) for the complex fistula (antg-asc-211)

Conditions: Perianal Fistula; Primary; Complex

Summary: this is an open follow-up clinical trial to evaluate a sustained efficacy and safety of antg-asc injection for 4 months (6 months after final dose injection) after phase ii clinical trial.


Eligibility criteria:
inclusion criteria: * the patients who have participated in antg-asc-210 clinical trial * the patients with complete closure at week 8 after last injection in antg-asc-210 trials * the patients who submit written informed consents and is able to obey requirements of trials exclusion criteria: * a patient who has a history of variant creutzfeldt jacobs disease or related diseases * a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue * a patient who has an autoimmune disease * a patient who has infectious diseases such as hepatitis b virus (hbv), hepatitis c virus (hcv) or human immunodeficiency virus (hiv) * a patient who has a symptom of septicemia or active tuberculosis (contain tuberculosis of anus and rectum) * a patient who is pregnant or breast feeding * a patient who is not willing to use effective contraceptive methods during the study * a patient who has inflammatory bowel disease * a patient who is sensitive to fibrin glue * a patient who have a clinically relevant history of abuse of alcohol or drugs, habitual smoker (who smoked more than 20 cigarettes a day) * a patient who is not able to understand the objective of this study or to comply with the study requirements * a patient who is considered to have a significant disease which can impact the study by investigator * a patient who is considered not suitable for the study by investigator * a patient who had a history of surgery for malignant tumor within the last five years (except carcinoma in situ) * a patient who has multisystemic wasting syndrome (such as tuberculosis, diabetes, thyroid disorders, tumor, etc.) * a patient who has taken cytotoxic drugs (such as immunosuppressants, corticosteroid, cytotoxic chemotherapy, anticoagulants, etc.) during long-term

Keywords: crohn's disease fistula complex
primaquine enantiomers in g6pd deficient human volunteers

Conditions: G6PD Deficiency

Summary: this study is a single center, prospective, cross-over phase 1 trial. eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over the course of 5 days.

each subject will receive a 15 mg dose of one enantiomer (spq or rpq or placebo) daily for up to 5 days, with careful monitoring of hematological parameters before and after each dose. in addition to the general cmp14 safety criteria, any subject who displays a fractional hemoglobin drop of 15% below his/her baseline value, then drug administration will stop (e.g. for baseline hgb of 14 g/dl, if there is at any point a decrease of 2.1 g/dl). hematocrit will be similarly monitored, with proportional stop criteria. elevation in total bilirubin to 2.0 mg/dl or greater will also be used as a stopping criterion. after stopping drug administration (5 days or whenever stop criteria are met), subjects will have a 3-week washout period, and the study repeated with the other enantiomer, and similarly with placebo.

Eligibility criteria:
inclusion criteria: * g6pd deficient, otherwise normal healthy adults aged 18 to 65 exclusion criteria: * known history of liver, kidney or hematological disease (other than g6pd deficiency) * known history of cardiac disease, non-sinus rhythm arrhythmia or qt prolongation * autoimmune disorders * report of an active infection * subject is pregnant or breast-feeding, or is expecting to conceive during the study.

Keywords: g6pd hemolysis primaquine pharmacokinetics malaria
role of endothelin-1 in flow-mediated dilatation

Conditions: Healthy Conditions

Summary: endothelial dysfunction of conduit arteries contributes to the increased morbidity and cardiovascular mortality in patients with essential hypertension and appears increasingly as an independent therapeutic target. we have shown previously that besides a decrease in the availability of no and other endothelium-derived vasodilators factors, the epoxyeicosatrienoic acids, an increase in the vasoconstrictor endothelin-1 (et-1) may play a role in the pathophysiology of this endothelial dysfunction. indeed, the local concentrations of endothelin-1 during the endothelium-dependent dilation of the radial artery in response to a sustained increase in blood flow decreased significantly in healthy volunteers controls but not in hypertensive patients. this lack of adaptation of the endothelinergic system could be due to a decreased clearance of endothelin-1 by endothelial etb receptors, potentiating the vasoconstrictor action of endothelin-1 mediated by eta receptor activation at the muscular level. however, to validate this hypothesis , it is needed to demonstrate the physiological role of eta receptor and etb in sustained flow-mediated dilatation of conduit arteries.


Eligibility criteria:
inclusion criteria: * male, caucasian, aged 18 to 35 years * non-smoking * resting heart rate\> 50 and \<90 bpm * sbp \<140 mmhg and dbp \<90 mm hg at rest in the supine position for 10 minutes * normal ecg exclusion criteria: * known allergy * intolerance to glyceryl trinitrate * intolerance to lidocaine * family history of hypertension * excessive alcohol consumption ( more than 50 g / day) * addiction or presumption of illicit drug use * subject refusing blood samples for serology of hepatitis b , c and hiv * history of illness or psychological or sensory abnormality that may prevent the subject to understand the requirements for participation in the protocol or prevents giving informed consent * metabolic or endocrine disease * immunological diseases * renal or hepatic impairment * ischemic or obstructive heart disease * neoplastic disease * gastrointestinal disease * neurological disease , intracranial hypertension , seizure disorders * compulsive overeating , bulimia, anorexia * severe psychiatric illness * presence of a clinically significant abnormality in laboratory tests carried out at the inclusion visit . * hbs ag , hcv ab , ac hiv 1 or hiv 2 positive . * the use of any drug in the range of less than 5 half-life time, in particular betablockers, sildenafil, cimetidine, amiodarone .

Keywords: endothelin, endothelium, flow-mediated dilatation
exercise program for individuals with sci in community

Conditions: Spinal Cord Injuries; Exercise Program; Rehabilitation

Summary: patients with spinal cord injury (sci) who have reduced mobility have difficulty exercising on their own without proper guidance in the community. community-based exercise programs are effective in removing various barriers such as lack of exercise programs, lack of experts, and lack of facilities. this study aims to verify the effectiveness and safety of a systematically designed customized exercise program for patients who live in the community and want to participate in exercise. our study results will serve as a basis for creating an environment where more individuals with sci can continue to exercise proactively and in the long term.

people with sci must perform regular exercise to improve function, quality of life, and reduce medical costs. however, sci people with reduced mobility have difficulty exercising on their own without proper guidance in the community. rehabilitation exercise for sci people should be applied based on accurate functional assessment, and risk factors related to exercise should also be assessed. community-based exercise programs are effective in removing various barriers such as lack of exercise programs, lack of experts, and lack of facilities. this study aims to verify the effectiveness and safety of a systematically designed customized exercise program for sci people who live in the community and want to participate in exercise. based on the results of many previous studies, the investigators expect that program participants will have improved cardiopulmonary endurance and quality of life. our study results will serve as a basis for creating an environment where more people with sci can continue to exercise preemptively and in the long term.

Eligibility criteria:
inclusion criteria: * spinal cord injury patients who are 19-65 years old or above and residing in the local community * individuals who can not walk independently for more than 10 meters without assistance from others * individuals whose elbow extensor strength is greater than muscle manual test (mmt) fair exclusion criteria: * individuals who have difficulty understanding the exercise program or expressing their symptoms * individuals who cannot participate in the intervention exercise program due to serious cardiovascular diseases * individuals who are deemed unsuitable for this study by a specialist in rehabilitation medicine due to other medical conditions
study of ar-14034 in participants with neovascular age-related macular degeneration (namd)

Conditions: Neovascular Age-related Macular Degeneration (nAMD)

Summary: the primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of ar-14034 sustained release (sr) in subjects with neovascular age-related macular degeneration (namd).

this study will be conducted in two stages. stage 1 is a 48-week, dose-escalation, open-label evaluation of ar-14034 sr. two cohorts will be enrolled, for an approximate total of 10 subjects. subjects in both cohorts will attend visits through week 48 for assessment of safety and preliminary treatment effects. stage 2 is a 56-week (plus extension) double-masked, active comparator, randomized, parallel group evaluation of ar-14034 sr compared with aflibercept. approximately 130 subjects will be enrolled and randomized 2:2:1 to ar-14034 sr lower dose, ar-14034 sr higher dose, or aflibercept dosed as labelled. subjects will attend visits through week 56 for assessment of safety and treatment effects. a 16-week open label extension phase will be conducted thereafter.

Eligibility criteria:
key inclusion criteria \[stage 1 and stage 2\]: * presence of an active choroidal neovascularization (cnv) lesion secondary to age-related macular degeneration (amd); * best corrected visual acuity (bcva) between 80 and 35 letters (20/25 to 20/200 snellen equivalent) in the study eye; * bcva greater than 34 letters (approximately 20/200 snellen equivalent) in the non-study eye; * media clarity and pupillary dilation in the study eye sufficient for all planned study procedures; * capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol; * other protocol-specified inclusion criteria may apply. \[stage 1\]: * greater than or equal to 3 and less than or equal to 6 prior treatments of an ocular anti-vegf medication within the 8 months prior to screening in the study eye, with demonstrated anatomic response, as assessed by the investigator. \[stage 2\]: * treatment-naïve, or initial diagnosis of exudative neovascular age-related macular degeneration (namd) in the study eye within 9 months before screening. key exclusion criteria \[stage 1 and stage 2\]: * history or current ocular disease in the study eye other than namd, that, might require medical or surgical intervention during the study; * structural damage to the macula that is likely to preclude improvement in visual acuity in the study eye after resolution of the namd; * any active intraocular or periocular infection or active intraocular inflammation; * treatment with ocular anti-vegf product within 28-days before week -1 \[stage 1\] or baseline \[stage 2\]; * uncontrolled glaucoma in the study eye; * uncontrolled blood pressure; * females of child-bearing potential who are pregnant, intending to become pregnant, nursing, or who are not willing to use an acceptable form of contraception for the duration of the study; * other protocol-specified exclusion criteria may apply.

Keywords: namd retina eyes ophthalmology
effects of lagenbone on bone mineral density

Conditions: Osteoporosis

Summary: to study the effects of the herbal supplement lagenbone on bone mineral density

to study the effects of the herbal supplement lagenbone on bone mineral density. lagenbone is a supplement based on the chinese herbal formula gui lu er xian jiao.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of osteoporosis * able to read and understand english * willing to receive routine dexa scans and comply with supplement schedule exclusion criteria: * pregnant, lactating, or having gestational diabetes * diagnosed with comorbid conditions that they are taking medication for e.g. acid reflux, hashimoto's/grave's disease, endometriosis, prostate, breast, uterine cancer, kidney disease, fibroids, psychological disorders * use of any medication known to interfere with bone mineral density * are taking any new medications/supplements/treatments/therapeutic exercise within the last two months for osteoporosis or bone density * involved in health-related litigation, claims * missing baseline visits * vegan or vegetarian * diagnosed with alzheimer's or demonstrating onset of dementia

Keywords: chinese medicine herbal medicine osteoporosis bone mineral density
dry needling versus strain-counterstrain on the upper trapezius

Conditions: Neck Pain

Summary: this study investigates the effect of two different techniques (dry needling and strain-counterstrain manual technique) on the upper trapezius myofascial trigger point (mtp). subjects with active or latent mtp in this location of the muscle will be identified and will be randomly assigned to one out of three groups: dry needling, strain-counterstrain or placebo manual technique. pain pressure threshold, provoked pain, pain at rest, neck disability and electromyography (emg) activity of the upper trapezius will be registered before and after six sessions of treatment.


Eligibility criteria:
inclusion criteria: * active myofascial trigger point at the upper trapezius exclusion criteria: * diagnosed fibromyalgia * cervical radiculopathy * facial neuralgia * coagulation alteration * cancer * allergy (included needles) * history of cervical or shoulder surgery * history of deep venous thrombosis * history of myopathy * history of infiltration at upper trapezius trigger point * anticoagulant medication * aspirin intake during the last 3 days * drug intake (aines, narcotics, antiepileptics, or any other analgesic medication) * pregnancy
s. aureus decolonization in hpn patients.

Conditions: Staphylococcus Aureus; Motility Disorder

Summary: this trial focusses on identifying the most effective and safe long-term s. aureus carriage decolonization strategy in home parenteral nutrition patients. half of the participants will receive a quick and short systemic antibiotic treatment combined with topical treatment, while the other half will receive only topical treatment on a periodic basis.

patients on home parenteral nutrition (hpn) are exposed to a lifelong risk of developing s. aureus bacteremia (sab). sab pose a threat to both catheter and patient survival and may lead to a permanent loss of vascular access. s. aureus carriage eradication has proven successful in prevention of s. aureus infections. s. aureus decolonization is a key strategy to maintain venous access and avoid hospitalization.

Eligibility criteria:
inclusion criteria: * patient is fully able to understand the nature of the proposed intervention. * written informed consent by the patient before entering the trial. * age ≥ 18 years. * estimated life expectancy ≥ 1 year. * patient colonized with s. aureus. exclusion criteria: * cannot be expected to comply with the trial plan (substance abuse, mental condition). * pregnant or breastfeeding women. * continuous exposure to methicillin-resistant s. aureus (mrsa; e.g. pig farmer). * allergy for chlorhexidine and betadine. * no options for oral and/or topical antibiotics due to allergies. * active s. aureus infection. * currently on treatment with antibiotics active against s. aureus. * decolonization (including mupirocin) treatment in the previous two months. * the presence of a nasal foreign body. * aspartate aminotransferase (ast) and alanine aminotransferase (alt) levels more than five times the upper limit of normal or liver failure.

Keywords: s. aureus home parenteral nutrition intestinal failure eradication decolonization
the turkish mastication observation and evaluation (t-moe) instrument

Conditions: Chewing Problem; Swallowing Disorder

Summary: the purpose of this study is to test the reliability and validity of the t-moe among pediatric patients with chewing disorders.

the purpose of this study is to test the reliability and validity of the t-moe among pediatric patients with chewing disorders.the internal consistency, test-retest reliability, and criterion validity of t-moe will be investigated. the internal consistency will be assessed using cronbach's alpha. intraclass correlation coefficient (icc) value with 95 % confidence intervals will be calculated for test-retest reliability. the criterion validity of the scale will be determined by assessing the correlation between the t-moe and karaduman chewing performance scale and tongue thrust rating scale.

Eligibility criteria:
inclusion criteria: * having chewing disorders aged between 18 months-12 years * being serebral palsy * being healthy children exclusion criteria: * no chewing disorders * a child aged below 6 months
a safety and efficacy study of fixed-combination bimatoprost and brimonidine in chronic glaucoma or ocular hypertension

Conditions: Glaucoma; Ocular Hypertension

Summary: this is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with lumigan® and alphagan® in patients with chronic glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * diagnosis of ocular hypertension or glaucoma * requires intraocular pressure (iop)-lowering therapy exclusion criteria: * cataract surgery in one eye * ocular laser or intraocular surgery within 6 months * refractive surgery in either eye * anticipated use of contact lenses during the study * expected use of artificial tears during the study